| ASSET | QUARTER | % RETURN |
|---|---|---|
BioCryst Pharmaceuticals (BCRX) | Q3 2013 | 366.67% |
GT Biopharma (GTBP) | Q3 2013 | 326.92% |
Quipt Home Medical (QIPT) | Q3 2013 | 272% |
Armata Pharmaceuticals (ARMP) | Q3 2013 | 240% |
Catalyst Pharmaceuticals (CPRX) | Q3 2013 | 235.16% |
Scienture (SCNX) | Q3 2013 | 228.57% |
Iovance Biotherapeutics (IOVA) | Q3 2013 | 227.5% |
Rockwell Medical (RMTI) | Q3 2013 | 211.48% |
Duos Technologies (DUOT) | Q3 2013 | 200% |
Dolphin Entertainment (DLPN) | Q3 2013 | 200% |
Daqo New Energy Corp ADR (DQ) | Q3 2013 | 187.61% |
Arrowhead Pharmaceuticals (ARWR) | Q3 2013 | 180.3% |
Xpel (XPEL) | Q3 2013 | 179.07% |
InnovAge (INNV) | Q3 2013 | 164.71% |
Sphere 3D (ANY) | Q3 2013 | 162.03% |
Arcturus Therapeutics (ARCT) | Q3 2013 | 161.45% |
Inovio Pharmaceuticals (INO) | Q3 2013 | 152.44% |
Cosmos Health (COSM) | Q3 2013 | 152% |
JinkoSolar (JKS) | Q3 2013 | 142.47% |
Galectin Therapeutics (GALT) | Q3 2013 | 134.59% |
Retractable Technologies (RVP) | Q3 2013 | 128.68% |
Emeren (SOL) | Q3 2013 | 126.82% |
NextTrip (NTRP) | Q3 2013 | 126.09% |
OLB (OLB) | Q3 2013 | 125% |
Supercom (SPCB) | Q3 2013 | 123.18% |
